Comparison between Cilnidipine and Amlodipine Besilate with Respect to Proteinuria in Hypertensive Patients with Renal Diseases
Open Access
- 1 January 2004
- journal article
- clinical trial
- Published by Japanese Society of Hypertension in Hypertension Research
- Vol. 27 (6), 379-385
- https://doi.org/10.1291/hypres.27.379
Abstract
Unlike other dihydropyridine calcium channel blockers (CCBs), cilnidipine has been reported to exert an N-type calcium-channel-blocking activity and to reduce sympathetic hyperactivity. This study compared cilnidipine and amlodipine with respect to their effects on renal function and proteinuria. Twenty-eight proteinuric hypertensive outpatients (13 men and 15 women, aged 62±2 years) who had been maintained on CCBs for more than 3 months were randomly assigned to a group receiving amlodipine besilate (14 patients) or a group receiving cilnidipine (14 patients). CCBs were increased in dosage or other drugs were added until blood pressure decreased below 140/90 mmHg, but no inhibitors of the renin-angiotensin (RA) system were added or changed in dosage. Before and at 6 and 12 months after randomization, the concentrations of urine protein, urine albumin, serum and urine creatinine (Cr), and serum β2-microglobulin were determined. The amlodipine group showed a significant increase in proteinuria, while the increase was suppressed in the cilnidipine group. The rate of increase in proteinuria at 12 months was 87% (95% confidence interval (CI) -10 to 184) of the baseline value with amlodipine and 4% (95% CI -69 to 77) of baseline with cilnidipine, a significant intergroup difference (p vs. 12 months, 1.36±0.20 vs. 1.50±0.23 mg/dl, p r =-0.477, p Hypertens Res 2004; 27: 379-385)Keywords
This publication has 25 references indexed in Scilit:
- Remission and Regression of Diabetic NephropathyHypertension Research, 2003
- Effect of Blood Pressure Lowering and Antihypertensive Drug Class on Progression of Hypertensive Kidney DiseaseResults From the AASK TrialJama-Journal Of The American Medical Association, 2002
- The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 DiabetesNew England Journal of Medicine, 2001
- Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 DiabetesNew England Journal of Medicine, 2001
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- Structure and Regulation of Voltage-Gated Ca2+ ChannelsAnnual Review of Cell and Developmental Biology, 2000
- Preserving renal function in adults with hypertension and diabetes: A consensus approachAmerican Journal of Kidney Diseases, 2000
- Nomenclature of Voltage-Gated Calcium ChannelsNeuron, 2000
- Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuriaThe Lancet, 1999
- Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathyKidney International, 1996